RPL17 and lymphoma: Currently, human anti-TIGIT monoclonal antibodies (mAbs) are being evaluated in Phase 1/2 clinical trials, both as monotherapy and in combination with anti-PD-1/PD-L1 antibodies or chemotherapy, for the treatment of malignant lymphomas.